Back to Search
Start Over
Development of a genetically engineered vaccine against feline leukemia virus infection.
- Source :
-
Journal of the American Veterinary Medical Association [J Am Vet Med Assoc] 1991 Nov 15; Vol. 199 (10), pp. 1423-7. - Publication Year :
- 1991
-
Abstract
- A genetically engineered subunit vaccine against FeLV infection was developed. The protective immunogen in the vaccine was a purified recombinant protein containing the entire amino acid sequence of FeLV subgroup A gp70 envelope protein. The optimal adjuvant was determined to be a highly purified saponin, QS-21, derived from Quillaja saponaria Molina. A vaccine formulation containing the recombinant protein, QS-21, and aluminum hydroxide was tested in specific-pathogen-free kittens and was shown to induce neutralizing antibodies as well as appreciable antibody responses to native gp70 by enzyme immunoassay and protein (western) immunoblot analysis and of whole virus preparations.
- Subjects :
- Adjuvants, Immunologic
Animals
Antibodies, Viral biosynthesis
Cats
Immunization, Secondary veterinary
Recombinant Proteins immunology
Specific Pathogen-Free Organisms
Vaccines, Synthetic immunology
Leukemia Virus, Feline immunology
Leukemia, Feline prevention & control
Retroviridae Proteins, Oncogenic immunology
Vaccination veterinary
Viral Envelope Proteins immunology
Viral Vaccines immunology
Subjects
Details
- Language :
- English
- ISSN :
- 0003-1488
- Volume :
- 199
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Journal of the American Veterinary Medical Association
- Publication Type :
- Academic Journal
- Accession number :
- 1666096